

## Indonesia

### Support for Vaccine: Inactivated Polio Vaccine (IPV)

#### This Decision Letter sets out the Programme Terms of a Programme

1. **Country:** Indonesia

2. **Vaccine grant number:** IDN-IPV-R

3. **Date of Decision Letter:** 24 April 2023

4. **Date of the Partnership Framework Agreement:** 30 December 2014

5. **Programme title:** New Vaccine Support (NVS), Inactivated Polio Vaccine (IPV), Routine, 2 doses

6. **Vaccine type:** Inactivated Polio Vaccine (IPV)

7. **Requested product presentation and formulation of vaccine:**  
*IPV, 5 doses/vial, liquid*

8. **Programme duration:**<sup>1</sup> 2016-2022

9. **Programme Budget (indicative):**<sup>23</sup> (subject to the terms of the Partnership Framework Agreement, if applicable)

	2016-2021	2022	2023	2024	2025	2026	Total <sup>2</sup>
Programme Budget(US\$)	41.828.000	9.831.723	-	-	-	-	51.659.723

10. **Vaccine introduction grant:**

Approval		
Year	Grant number	Amount (US\$)
2015	IDN-IPV-R-VIG-MOH	3.688.500
2020	IDN-IPV-R-VIG	100.000

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

<sup>3</sup> This is the amount that Gavi has approved.

**11. Product switch grant:**

Approval		
Year	Grant number	Amount (US\$)
2022	IDN-IPV-R-PSG	1.144.250

**12. Indicative annual amounts:<sup>3</sup>** (subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2016-2021	2022	2023
Number of vaccine doses	-	4.741.800	-
Number of AD syringes	-	4.829.200	-
Number of re-constitution syringes	-	-	-
Number of safety boxes	-	48.300	-
Annual Amounts (US\$)	41.828.000	9.831.723	-

**13. Procurement agency:** Not applicable

**14. Self-procurement:**

Self-procurement applies. Please refer to the Partnership Framework Agreement terms and conditions.

**15. Co-financing obligations:**

**Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.**

**16. Operational support for campaigns:**

Not applicable

**17. Additional Reporting Requirements:**

Reports and other information :	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 15 May</p>

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
---	------------------------------------

---


**18. Financial clarifications:**

Not applicable

---

**19. Other conditions:**

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.



Thabani Maphosa  
Managing Director,  
Country Programmes Delivery

27/04/2023

